Enterprise Value
457.5M
Cash
157.9M
Avg Qtr Burn
-9.012M
Short % of Float
19.45%
Insider Ownership
40.39%
Institutional Own.
57.70%
Qtr Updated
03/31/24
Drug Pipeline
Powered by
![](/BPIQ_Pill.png)
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
GH001 (inhalable mebufotenin) (5-MeO-DMT) Details Treatment Resistant Depression | Phase 2b Data readout | |
GH001 (inhalable mebufotenin) (5-MeO-DMT) Details Bipolar depression, Postpartum depression | Phase 2a Data readout | |
GH002 (IV mebufotenin) (5-MeO-DMT) Details Treatment Resistant Depression | Phase 1 Update | |
GH001 (inhalable mebufotenin) (5-MeO-DMT) Details Treatment Resistant Depression | Phase 1 Initiation |